Physician profile
Aman Rajpal
NPI 1104187566
$24,516.73
in general payments reported to CMS, 2019-2025
9 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.27 · 2020: $96.17 · 2022: $129 · 2023: $378 · 2024: $328 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $1,847 · Travel and Lodging: $1,738 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,110.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $1,846.60 |
| Travel and Lodging | $1,738.33 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $13,558.54 | 2025 | Olezarsen |
| Madrigal Pharmaceuticals | $6,673.56 | 2025 | Rezdiffra |
| Novo Nordisk INC | $3,693.38 | 2019-2025 | Ozempic, Wegovy |
| Corcept Therapeutics | $270.54 | 2024-2025 | Korlym |
| Abbott Laboratories | $99.86 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $99.49 | 2023 | |
| Novartis Pharmaceuticals Corporation | $74.08 | 2024 | |
| Medtronic, INC. | $26.57 | 2025 | Minimed 780g |
| Mannkind Corporation | $20.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Rajpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.